KCT0004424
Recruiting
未知
A 12week, Randomized, Double-blind, Placebo-Controlled Clinical Trial for the Evaluation of the Efficacy and Safety of KD501 on Memory Improvement
Wonkwang University. Iksan Korean Medicine Hospital0 sites80 target enrollmentTBD
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Not specified
- Sponsor
- Wonkwang University. Iksan Korean Medicine Hospital
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\) Adult male and female aged 20 years or older and 65 years old, complaining of memory degradation
- •2\) Those who can read Korean literature
- •3\) K\-WMS\-IV's simplified recognition status test results are above the boundary line, and those with an auditory memory index or visual memory index of 85 or lower, or those with an SVLT or RCFT score of SNSB\-II compared with the same age and education level (immediately count of points or number of delayed recovery points).
- •4\) A person who agrees to participate in the human application test before the start of the human application test and prepared a written consent form
Exclusion Criteria
- •1\) Those who are hospitalized for malignancy, severe cerebrovascular diseases (such as cerebral infarction, cerebral hemorrhage, etc.) or severe heart disease (an arrhythmia requiring unstable angina, myocardial infarction, and heart failure) or who have not passed three months since discharge from hospitalization
- •2\) Those who are currently suffering from schizophrenia or have a history
- •3\) Current DSM\-V major depression disorder.
- •4\) A person who has 16 or more points of depression according to CES\-D test results
- •5\) Those with diseases that are accompanied by a decrease in cognitive function, such as dementia, Parkinson's and cerebral infarction (the criteria for dementia diagnosis are based on DSM\-V.)
- •6\) Visit 1 Persons with experience in administering estrogen replacement therapy (excluding local application agents) within two months of standard visit1
- •7\) Anyone who has experience in administering medications (alarm credit, degenerative disease solvents, brain function improvement, and tricyclic antidepressants) that can affect cognitive function or memory improvement within four weeks of visit1;
- •8\) Those who have taken health function foods related to improvement of cognitive function or memory within two weeks of visiting 1;
- •9\) Those with a daily dose of vitamin E of 400 IU or more are expected to decrease the dose;
- •10\) Alcohol abuse and heavy reliance on alcohol
Outcomes
Primary Outcomes
Not specified
Similar Trials
Recruiting
Not Applicable
Clinical Trial for the evaluation of the efficacy and safety of 7-MEGATM500 on the Skin wrinkle improvementDiseases of the skin and subcutaneous tissueKCT0004592Vitech90
Completed
Not Applicable
A Clinical Trial for the evaluation of the efficacy and safety of RW0117 on dyspepsiaKCT0005265Richwood Trading Company, LTD.100
Not yet recruiting
Not Applicable
The efficacy and safety of CT20S on the Skin wrinkle improvementKCT0004447P&K Skin Research Center120
Recruiting
Not Applicable
A human study to evaluate the effect of CKDB001 on Cognitive-enhancing functioKCT0009298Chong Kun Dang Bio100
Unknown
Phase 2
Evaluate the Efficacy of BGG492 as Adjunctive Treatment in Patients With Refractory Partial Onset SeizuresCTRI/2010/091/001332ovartis Health care Private Limited57